Bronchodilators oxidation

P-Blockers, benzodiazepines, NSAIDs, barbiturates NSAIDs, protease inhibitors, P-blockers, benzodiazepines Antimalarials, NSAIDs, P-blockers, bronchodilators Phosphine oxides, NSAIDs, anticonvulsants Bronchodilators, P-blockers... 

It is evident that some leeway is available in the substituents tolerable in the m-position. The bronchodilator sulfonterol (28) is descended from this observation. Chloromethylanisole (29) is reacted with methylmereaptan to give 30, and the newly introduced group is oxidized to the methyl-sulfonyl moiety of 31 with hydrogen peroxide. Ether cleavage, acetylation and Fries rearrangement of the phenolic acetate produces 32, which is next brominated with pyrrolidinone hydrobromide tribromide and then oxidized to the glyoxal (33) with dimethyl sulfoxide. 

Besides neuropeptides, nitric oxide is an inflammatory mediator in the airways, which is also a vasodilator and a neurotransmitter. Nitric oxide is produced by the enzymatic action of nitric oxide synthetase on L-arginine. Airways contain this enzyme in three different forms, two of which termed neuronal and endothelial nitric oxide synthetase are constitutive whereas the third form called inducible nitric oxide synthetase is inducible. The inflammatory cytokines including IL-1 and TNF-a augment the expression of inducible nitric oxide synthetase in human airway epithelial cells. Nitric oxide causes bronchodilation as a result of the relaxation of bronchial smooth muscles. It has also been suggested that nitric oxide is the neurotransmitter of the inhibitory NANC bronchodilation. The detrimental effects of nitric oxide include airway inflammation and vasodilation. It causes airway edema by increasing the erudition of plasma due to increased blood flow to postcapillary venules. The increased blood flow may also contribute to an increased mucus secretion. The role of nitric oxide in inflammatory responses has not yet been established. 

In contrast, noradrenergic sympathetic innervation of the airways is sparse, and these fibers do not appear to play a major role in controlling airway diameter. Bronchodilation may be brought about by nonadrenergic, noncholinergic nerves releasing nitric oxide since nitric oxide synthase inhibitors have been shown to reduce bronchodilation produced by electrical field stimulation in vitro. 

Modern inhalation anesthetics are nonexplosive agents that include the gas nitrous oxide as well as a number of volatile halogenated hydrocarbons. As a group, these agents decrease cerebrovascular resistance, resulting in increased perfusion of the brain. They cause bronchodilation and decrease minute ventilation. Their clinical potency cannot be predicted by their chemical structure, but potency does correlate with their solubility in lipid. The movement of these agents from the lungs to the different body compartments depends upon their solubility in blood and various tissues. Recovery from their effects is due to redistribution from the brain. 

Bromonitrile oxide, see Formonitrrle oxide, bromo-Bronchodilators... 

Gaston, B., Reilly, J., Drazen, J.M. etal. (1993b). Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc. Natl. Acad. Sci. USA 90, 10957-10961. 

Dupuy, P., Shore, S. A., Kim, K., Drazen, J. M., and Zapol, W. M. (1993a). Bronchodilator action of inhaled nitric oxide in histamine, leukotriene D4, and neurokinin A constricted guinea pigs. Am. Rev. Respir. Dis. 147(Suppl. 4), A288 (abstr.). 

Nitric oxide does not cause arrhythmias or constipation. It causes bronchodilation and may hasten graft rejection. Nitric oxide does cause pulmonary vasodilation. The answer is (E). 

From the data of Table XI it is apparent that bronchodilator activity is drastically reduced by substitution on C2-C4. On the other hand, methyl substitution at C5 or at Cg provided compounds with equivalent or even enchanced potency. It is conceivable that the increased activity of the 5-methyl analog, which would not be expected to retard p-oxidation, is in fact a reflection of increased resistance to PG 15-dehydrogenase. 

Amin et al. have observed that vasicinone, an auto-oxidation product of vasicine from extracts of A. vasica leaves, causes definite bronchodilation in the presence of histamine-induced bronchospasm, slight hypotension and a positive cardiac inotropic action with increased coronary flow. The investigators attribute the bronchodilator effect of vasaka leaves to the small amount of vasicinone produced by auto-oxidation of vasicine (cited after 124). Mehta et al. (136) have isolated 1-vasicinone from A. vasica and demonstrated that it is not an artifact as it has bronchodilator activity in contrast to the bronchoconstrictor activity of 1-vasicine. 

---